TP53 and renal cell carcinoma: An extensive analysis of 33 TCGA studies showed that the effects of TP53 mutations on patients’ prognosis were statistically significant in nine malignancies (lung adenocarcinoma, hepatocellular carcinoma, HNSCC, acute myeloid leukaemia, clear-cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC, uterine endometrial carcinoma and thymoma).20 Although this method can be considered “quick and useful”, this approach does not take into account some biochemical and functional characteristics of single TP53 mutations.